TY - CHAP
T1 - Organophosphate intoxication
T2 - Molecular consequences, mechanisms and solutions
AU - Geyer, Brian C.
AU - Evron, Tama
AU - Soreq, Hermona
AU - Leket-Mor, Tsafrir
N1 - Funding Information:
This work was funded in part by a DARPA research contract #N66001-01-C-8015 (to TSM & HS) and by the National Institute of Health CounterACT Program through the National Institute of Neurological Disorders and Stroke under the U-54-NSO58183-01 award – a consortium grant awarded to USAMRICD and contracted to TSM under the research cooperative agreement number W81XWH-07-2-0023. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Federal US government. We would like to thank Charles Kazilek (School of Life Sciences Visualization Laboratory at Arizona State University) for his contribution to Figure 46.2 .
PY - 2009
Y1 - 2009
N2 - The essential role of acetylcholinesterase (AChE) in the neuromuscular junction (NMJ) predicts severe consequences following loss of function by its irreversible inhibition. The vital role of the acetylcholine-hydrolyzing enzyme AChE in terminating cholinergic neurotransmission has been recognized for almost as many years. Anticholinesterases can be commonly encountered as industrial pesticides, weapons of war, Alzheimer's medications as well as the natural toxins of many organisms including fungi, plants, and animals. Exposure to clinically relevant doses of anticholinesterases results in immediate and multisystem physiological disturbances that underscore the broad anatomical distribution of the mammalian cholinergic system. The body adapts to the insult and attempts to compensate for the cholinergic dysregulation by inhibitor-enzyme interactions, NMJ remodeling, and changes in circulating cytokine profiles. In addition the loss of synaptic cholinergic regulation by AChE inhibition has immediate negative consequences for mammalian physiology. The severe multisystem clinical presentation of anti-ChE intoxication demonstrates the essential and ubiquitous nature of the mammalian cholinergic system. Current medical intervention in the case of acute exposure to anticholinesterase agents includes use of the muscarinic receptor antagonist atropine to block overstimulation, and oximes to reactivate the OP-modified AChE. The reversible carbamate inhibitor, pyridostigmine bromide, is also used for prophylaxis.
AB - The essential role of acetylcholinesterase (AChE) in the neuromuscular junction (NMJ) predicts severe consequences following loss of function by its irreversible inhibition. The vital role of the acetylcholine-hydrolyzing enzyme AChE in terminating cholinergic neurotransmission has been recognized for almost as many years. Anticholinesterases can be commonly encountered as industrial pesticides, weapons of war, Alzheimer's medications as well as the natural toxins of many organisms including fungi, plants, and animals. Exposure to clinically relevant doses of anticholinesterases results in immediate and multisystem physiological disturbances that underscore the broad anatomical distribution of the mammalian cholinergic system. The body adapts to the insult and attempts to compensate for the cholinergic dysregulation by inhibitor-enzyme interactions, NMJ remodeling, and changes in circulating cytokine profiles. In addition the loss of synaptic cholinergic regulation by AChE inhibition has immediate negative consequences for mammalian physiology. The severe multisystem clinical presentation of anti-ChE intoxication demonstrates the essential and ubiquitous nature of the mammalian cholinergic system. Current medical intervention in the case of acute exposure to anticholinesterase agents includes use of the muscarinic receptor antagonist atropine to block overstimulation, and oximes to reactivate the OP-modified AChE. The reversible carbamate inhibitor, pyridostigmine bromide, is also used for prophylaxis.
UR - http://www.scopus.com/inward/record.url?scp=84875809228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875809228&partnerID=8YFLogxK
U2 - 10.1016/B978-012374484-5.00046-8
DO - 10.1016/B978-012374484-5.00046-8
M3 - Chapter
AN - SCOPUS:84875809228
SN - 9780123744845
SP - 691
EP - 717
BT - Handbook of Toxicology of Chemical Warfare Agents
PB - Elsevier Inc.
ER -